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A B S T R A C T
Purpose: The objective of our study was to gain further insight into the extent of local metabolic
alterations in patients with idiopathic generalised epilepsy (IGE), respectively, the subgroup with
generalised tonic–clonic seizures (GTCS). The extent of regional metabolic involvement perhaps
indicates the key structures in generation of seizures and involvement of speciﬁc network of
dysfunction.
Methods: Using the multi-voxel technique at a 3 T MRI Scanner metabolite levels of 25 age-matched
healthy controls and 18 patients with GTCS were obtained from the basal ganglia, insular cortex,
cingulum, hippocampus and along both hemispheres in the fronto-parietal white and grey matter.
Results: Group analysis of GTCS patients versus healthy controls revealed signiﬁcant (p < 0.05) decrease
of tNAA in the cortex of the central region and cingulum, but also in the thalami. Glx was elevated
broadly in both hemispheres, in particular in central region, cingulum, insular cortex and left putamen,
yet also in the right thalamus. Cho and mI demonstrated a signiﬁcant coincidental decrease pronounced
in the grey and white matter of the central region. Signiﬁcant metabolic correlation (p  0.05) based on
tNAA, respectively, Glx occurred between the thalamus and the central region, cingulum, putamen and
medial frontal cortex. In patients with >2 tonic–clonic seizures in the last 12 months a trend towards
higher Glx and lower tNAA levels was observed.
Discussion: Our results demonstrate the altered metabolic interconnection of cerebral anatomic regions
in patients with GTCS, in particular the major role of basal ganglia-central region relay in seizure
generation.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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MRI techniques as proton magnetic resonance spectroscopy
(1H-MRS) give non-invasive insights to diverse functional and
structural alterations in patients with neurological disorders as
epilepsy.1–9 The multi-voxel technique refers to chemical shift
imaging (CSI) which combines features of MR imaging and
spectroscopy yielding data from multiple adjacent voxels eventu-
ally covering the whole brain.10–12 1H-MRS performed at a higher
magnetic ﬁeld strength as 3 T has the advantages of higher signal-
to-noise ratio (SNR) and improved spectral resolution in clinically
acceptable scan times. Due to the advantages of high ﬁeld
strengths and cumulative availability of 3 T MRI multi-voxel
techniques are increasingly used in clinical settings. Commonly* Corresponding author. Tel.: +49 09131 85 39388; fax: +49 0 9131 85 36179.
E-mail address: marc.doelken@uk-erlangen.de (M.T. Doelken).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.07.005distinguishable metabolites include total N-acetyl aspartate
(tNAA), choline (tCho), myo-inositol (mI), glutamate (Glu) plus
glutamine (Gln) (Glu + Gln = Glx) and creatine (tCr). In patients
with idiopathic generalised epilepsy (IGE) most previous studies
were implemented using the single-voxel technique (SVS),
acquiring a single spectrum from a deﬁnite volume of tissue as
an integral.5,6,13–15 This acquisition is fairly fast (3 min) and a
spectrum is easily obtained, however it provides limited informa-
tion about regional distribution of brain metabolites. Only few
recent studies implemented the multi-voxel technique in clinical
settings with IGE.1,3,4
Juvenile myoclonic epilepsy (JME), childhood absence epilepsy
(CAE) and epilepsy with generalised tonic–clonic seizures only
(GTCS) are the most common syndromes of IGE with distinct
electroclinical features and prognosis.16 They are considered to
share absence of magnetic resonance imaging (MRI) ﬁndings and
several clinical features, however differ in their predominant
seizure types.17 In previous single- and multi-voxel 1H-MRSvier Ltd. All rights reserved.
Table 1
Summary of clinical data of patients with GTCS [group I <2 seizures in the last 12
months; group II >2 seizure in the last 12 months; * =1/5 patient with previous
Levetiracetam medication had no current medication due to intolerance of
Levetiracetam; SD= standard deviation].
Clinical data GTCS
Gender male/female 10/18 (56%); 8/18 (44%)
Age (years) Mean 28; min 18; max 39
Hand preference 17/18 (94%) right handed
Duration of epilepsy (years) 12  SD 4




Seizure frequency under medication in
the last 12 months
I. 9/18 2 tonic–clonic
seizures/12 months
II. 9/18 >2 tonic–clonic seizures/12 months
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metabolic alterations were mainly found in the thalamic and
prefrontal tNAA levels.1,3–6,13–15 The neurochemical abnormalities
are considered to reﬂect thalamocortical dysfunction, however,
metabolic alterations of speciﬁc cerebral networks in particular the
extend of metabolic alterations in the mentioned subgroups still
remain ambiguous.1,3–6
Using the multi-voxel technique at a 3 T scanner our purpose
was to gain further insight into the extent of local metabolite
alterations in patients with GTCS within grey matter sites of the
basal ganglia including thalamus and putamen, insular cortex,
hippocampus, cingulum and along both hemispheres in the fronto-
parietal white and grey matter. Our results might contribute
further data regarding the extent of regional metabolic alteration,
respectively, involvement of a speciﬁc network of dysfunction in
patients with GTCS. Additionally, metabolic impairment in the
context of seizure frequency was evaluated.
2. Patients and methods
2.1. Subjects–inclusion criteria
18 patients with diagnosis of GTCS16 (10 men, 8 women; age
range 18–39 years, average 28 years) were included. Demographic
and clinical data were obtained through interviews with the
patients and by reviewing hospital charts. Diagnosis of idiopathic
epilepsy, respectively, GTCS was based on seizure history and
semiology, EEG and interictal  ictal video-EEG. Estimation of the
frequency of seizures was based on questioning of the patients. The
status of seizure control was deﬁned as follows: group I <2 tonic–
clonic seizures in the last 12months, group II>2 tonic–clonic seizures
in the last 12 months. Only patients with negative ﬁndings in high-
ﬁeld MRI were enclosed in the study. To exclude missed subtle
pathological ﬁndings in conventional MRI as, e.g. cortical dysplasia or
heterotopia a voxel-basedmorphometric analysiswith a T1-weighted
MRI volume data set was additionally performed using a technique
based on free available statistical parametricmapping software (SPM)
assembled by Huppertz et al.18 Major clinical data of the eventually
enclosed patients are listed in Table 1. 1H-MRS was shifted if the last
tonic–clonic seizure was within the last 14 days.
The normal reference group comprised 25 age-matched healthy
young adults (12 men, 13 women; age range 19–40 years, average
27 years), whowere equally examinedwithmulti-voxel 1H-MRS at
the same 3 T scanner. All subjects were free from neurological or
psychiatric diseases, and their brain MRI scans were normal. All
subjects participated voluntarily and informed consent was
obtained for each subject. Studies have shown that metabolite
values do not signiﬁcantly vary in adolescents and adults.19–21
Therefore, we recruited adults from a limited age range, thus
expecting no signiﬁcant variation of the metabolites due to age.
The study was approved by the local ethics committee.
2.2. Multi-voxel MR spectroscopy
Multi-voxel 1H-MRSwas performed at a 3 T SiemensMagnetom
Trio (Siemens Medical Solutions, Erlangen Germany) with an 8
channel head array coil. Both patients suffering from epilepsy and
healthy adults were equally examined using multi-voxel MRS
sections acquired according to Fig. 1. The multi-voxel MRS sections
in Fig. 1a–f consisted of 16 16 voxels. The volume of interest (VOI)
of the multi-voxel MRS sections was 180 mm 180 mm 10 mm,
thus the volumeof one voxelwas (180/16)2  10 = 1.3 cm3. The ﬁrst
multi-voxel section (Fig. 1a and b) encompassed parts of the pre-
cuneus, gyrus cinguli (referred to as cingulum), aswell as frontal and
parietal grey and white matter (Fig. 1d). The second multi-voxel
section (Fig. 1a and b) included the thalamus, putamen and insularcortex (Fig. 1e). The last multi-voxel MRS section (Fig. 1c) in the
hippocampi comprised the anterior portion of the hippocampus
(H1) as well as the medial (H2) and posterior portion (H3) (Fig. 1f).
The positioning of the multi-voxel MRS sections was performed on
voxels graphically prescribed from T2-weighted images (TR
4000ms, TE 94ms, slices 19–21, FOV 200, Matrix 218  384). The
voxelswere thenarranged into symmetrical pairs oneach sideof the
midlinebyanexperiencedneuroradiologist.Allmeasurementswere
performed by the same neuroradiologist to ensure reliable and
comparable positioning of the sections. The caudo-mesial portion of
frontal lobeswasavoidedowing tosusceptibilityartefactsgenerated
from this region. Fig. 2a–c shows examples of acquired spectra.
For all three multi-voxel MRS sections a 2D-MRS sequence was
used (point-resolved spectroscopy (PRESS), TE = 30 ms,
TR = 1700ms, averages 128). Corresponding unsuppressed water
spectrawith equal TE andTRwere additionally acquired. Before data
collection the automatic shim provided by the manufacturer was
carried out to optimise ﬁeld homogeneity. In some cases manual
post-shimming was performed.
2.3. Post-processing
The following brain metabolites were selected for further
analysis: totals NAA (tNAA, the sum of N-acetyl aspartate (NAA)
and N-acetylaspartylglutamate (NAAG)), glutamate (Glu), gluta-
mate (Glu) plus glutamine (Gln) (Glu + Gln = Glx), total Cho (tCho,
predominantly glycerophosphocholine (GPC) and phosphocho-
line (PCh)), myo-Inositol (mI) and total Cr (tCr, the sum of Cr and
phospocreatine (PCr)). tNAA, Glu, Glx, tCho and tCr were
quantiﬁed using LCModel,22 which is a user-independent
frequency domain spectral ﬁtting program (Fig. 2d). LCModel
quantiﬁes metabolite values referencing to the unsuppressed
water peak. Water scaling and ﬁtting were carried out automati-
cally. Spectra were corrected for T1- and T2-relaxation according
to previous studies.23,24 Estimated uncertainties by Cramer-Rao
Lower Bounds (CRLB) served as main guidelines for judging the
spectra of absolute metabolite values. Only metabolite spectra
with LCModel estimated uncertainty of <15% standard deviation
(SD) (SD < 20% for Glu and Glx) and spectra with a signal to noise
ratio (SNR) above four were included in this study. Spectra with a
Full Width at Half Maximum (FWHM) >0.065 ppm in the central
region and a FWHM>0.08 ppm in the thalamus & insular cortex &
hippocampus were not included in the study. LCModel provides
estimates of the individual values of Glu and Gln, however, owing
to substantial overlap even at 3 T the sum of the values of these
two components (Glx) is more reliably determined than the
individual components. As to Glu more than 60% of the spectra
met the study criteria mentioned above (e.g. SD < 20%), therefore
Fig. 1. This ﬁgure shows the arrangement of three multi-voxel spectra (a–c) into symmetric pairs on each side of the midline including frontal and parietal grey and white
matter, parts of the pre-cuneus, gyrus cinguli (referred to as cingulum), as well as the thalamus, putamen, insular cortex and hippocampus. (a–c) Show reference lines and
correct positioning of the multi-voxel spectra. (d–f) Indicate the voxel inclusion in relation to brain anatomy [Abbreviations: cr-C = central region Cortex; cr-W = central
regionwhitematter; ci = cingulum; pcu = pre-cuneus; lf-C = lateral frontal Cortex; f-W = frontal lobewhitematter; mf-C = medial frontal Cortex; In = insular; Th = thalamus;
P = putamen; Hip = Hippocampus].
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as a single value was not included because less than 15% of the
spectra met the study criteria (SD < 20%). For further details see
Hammen et al.25
The amount of CSF in a voxel was found by manually
segmenting CSF on T2-weighted images and was expressed as a
percentage of voxel volume. The correction of each metabolite for
CSF dilution was carried out by the formula: Ccorr = (Cmeas  100)/
(100  CSFperc). Cmeas refers to measured value of metabolite of the
whole voxel. CSFperc corresponds to the percentage of CSF in the
voxel.
We did not perform automatic morphometric segmentation on
the precise amount of grey and white matter in a voxel. However,
the included voxels in the respective anatomic region in both
hemispheres were carefully selected by one experienced neurora-
diologist preceding evaluation with LCModel. The location of a
voxel, e.g. in the peripheral frontal and parietal region, was
manually considered within the cortex when comprising >60%
grey matter.
The number of spectra averaged for each anatomic region in
both cerebral hemispheres was (Fig. 1): thalamus = 2; puta-
men = 1; insular cortex = 3, pre-cuneus = 2, cingulum = 4; central
region white matter = 3; frontal lobe white matter = 3; central
region cortex = 3; medial frontal cortex = 3; lateral frontal
cortex = 3.2.4. Statistics
Statistical analysis was carried out by SPSS 15.0 and R 2.6.2.26
Normal distribution of the metabolite concentrations within the
anatomic regions was checked by the Shapiro–Wilk-Test. Differ-
ences between patients and controls with respect to age were
assessed using Student’s t-test (Table 1). For group analysis between
healthy controls and epilepsy patients within the anatomic regions
we used one-dimensional analysis of variance (ANOVA) based on
p< 0.05 (Figs. 3 and 4). Individual regional metabolic level was
considered as abnormal if exceeding a plus or minus 1.5 standard
deviation (SD) shift of the mean of the healthy control group (Table
2). The metabolic correlation within the epileptic network
(hippocampus, thalamus, putamen and central region) was tested
for tNAA and Glx with Pearson’s correlation (p-value 0.05).
Additionally, Pearson’s correlation for tNAA and Glx against
frequency of seizures was applied. Analysis of variance (ANOVA)
was performed for tNAA and Glx for concurrent medical treatment.
3. Results
3.1. Group analysis GTCS versus healthy controls
Table 1 summarises the clinical data of the enclosed patients
with GTCS. Figs. 3 and 4 delineate the overall extent of metabolic
Fig. 2. Examples of attainedmulti-voxel spectra of the cingulum (a), thalamus (b) and hippocampus (c). Additionally, LCModel evaluation of metabolite values with baseline-
ﬁt is delineated (d).
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The mean levels of the single metabolites in Figs. 3 and 4 are
displayed by a colour code and matched with axial T2w brain
image (green/red = reduction/increase of the metabolite in com-
parison to healthy controls – see colour bar p values). The
hippocampi are not shown due to inconspicuous results regarding
all metabolites.
In summary, group analysis of GTCS patients versus healthy
controls revealed signiﬁcant (p < 0.05) decrease of tNAA in the
cingulum and cortex of the pre- and postcentral region (in the
following referred to as ‘‘central region’’). Additionally, a decrease
(p < 0.05) of tNAA was observed in the thalami. Glx was elevated
broadly in both hemispheres, most of all in central region,
cingulum, insular cortex and left putamen. A signiﬁcant increase
(p < 0.05) was seen also in the right thalamus. As to Glu a
signiﬁcant (p > 0.05) increase was noticed in the white matter of
the central region and, corresponding to Glx, pronounced in the left
putamen and both insular cortex. Cho and mI demonstrated a
signiﬁcant coincidental decrease (p < 0.05) in particular in the grey
and white matter of the central region. Moreover, Cho was
signiﬁcantly decreased (p < 0.05) in the left thalamus.
3.2. Individual results in comparison to healthy controls
Table 2 indicates the individual regional results of the patients
with GTCS in comparison to healthy controls. In summary, tNAA
was eminently reduced in patients in the grey and white matter in
the central region (up to 17.6%), in the cingulum (up to 38.9%) and
thalamus (up to 23.1%), while Glx showed corresponding increasein these regions (central region cortex up to 27.3%; central region
white matter up to 42.9%, thalamus up to 16.7%). Additionally, Glx
was elevated in the medial frontal cortex (up to 53.8%). Further
signiﬁcant increase of Glx was noticed also in the putamen (up to
20%) and insular cortex (up to 25%). Glu was increased in the
central region (up to 17.6%), respectively in the frontal lobe white
matter (up to 14.3%) as well as in the insular cortex (up to 6.2%),
putamen (up to 30%) and thalamus (up to 33.3). Cho and mI
demonstrated a signiﬁcant concomitant decrease mainly in the
grey and white matter in the central region (up to 27.8% mI; up to
16.7% Cho), in the medial frontal cortex (up to 15.4% Cho; up to
23.1% mI) and in the thalamus (up to 16.7% Cho; up to 8.3% mI).
3.3. Correlations within the epileptic network
Signiﬁcant correlation within the epileptic network with
p  0.05 based on tNAA, respectively Glx occurred between the
thalamus and the central region, cingulum and putamen. As to Glx
signiﬁcant correlation was also noticed between the thalamus and
themedial frontal cortex. In contrast, no signiﬁcant correlationwas
observed in controls between thalami and other structures.
3.4. Relation to age, duration of epilepsy and seizure frequency
There was no signiﬁcant correlation between tNAA or Glx and
age, respectively duration of epilepsy. However, in patients with
>2 tonic–clonic seizures in the last 12 months a trend towards
higher Glx values and lower tNAA levels was observed in the
thalamus (tNAA p = 0.08; Glx p = 0.07), insular cortex (tNAA
Fig. 3. This ﬁgure displays the overall extent of hemispheric metabolic impairment in the respective anatomic regions of the GTCS patients in comparison to healthy controls.
Themean levels of singlemetabolites are displayed by a colour code (colour bar on right bottom side of the ﬁgure; EP = epilepsy patients; HC = healthy controls) andmatched
with axial T2w brain images: green/red = reduction/increase of the metabolite in comparison to healthy controls (see colour bar p values). An decrease of tNAA with
corresponding increase of Glx in the cingulum and cortex of the pre- and postcentral region (referred to as ‘‘central region’’) was noticed. Additionally, Cho and mI were in
particular reduced in the central region. Further details are presented within the text. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the web version of this article.)
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cingulum (tNAA p = 0.05; Glx p = 0.01), central region grey matter
(tNAA p = 0.04; Glx p = 0.002) and medial frontal cortex (tNAA
p = 0.03; Glx p = 0.02).
3.5. Relation to concurrent medical therapy
We did not ﬁnd signiﬁcant difference in tNAA and Glx in any
regionwhen comparing patientswith differentmedical treatments
(ANOVA, p > 0.05).
4. Discussion
In agreement with recent reports applying both single- and
multi-voxel techniques in different anatomic brain regions at
1.5 T scanners our results at 3 T document the major role of
‘‘basal ganglia-central region relay dysfunction’’, respectively,
the extent of (sub-)network involvement in patients with
GTCS.1,4,5,15 However, if the metabolic alterations, e.g. in the
central region are primary or secondary to the origin of theseizures remains uncertain, particularly because of further
partial metabolic abnormalities in other regions (potential
sub-networks). There is relative inhomogeneity in published
IGE groups, sometimes including IGE sub-syndromes that were
not classiﬁable. Patients with GTCS in this study were selected
according to the ILAE classiﬁcation.17 Additionally, we per-
formed a voxel-based morphometric analysis to exclude missed
subtle pathologic processes in conventional MRI as, e.g. cortical
dysplasia or heterotopia.18 Of course, microdysgenesis cannot
be excluded using this method as well. In fact, neuropathologic
studies actually demonstrated distributed cortical and subcorti-
cal microdysgenesis in patients with IGE,27 which could
form the basis of generalised involvement of the brain during
seizure.
There are several theories proposed to explain the pathophysi-
ology of generalised epilepsy.28–30 Only few 1H-MRS reports
addressed the key structures in patients with GTCS, respectively
the extent of metabolic alteration within brain networks.1,5,15 We
were unable to ﬁnd a clinical study as to GTCS patients covering
such a wide brain range.
Fig. 4. This ﬁgure displays the overall extent of metabolic impairment in the basal ganglia of the GTCS patients in comparison to healthy controls. The mean levels of single
metabolites are displayed by a colour code (colour bar on right bottom side of the ﬁgure; EP = epilepsy patients; HC = healthy controls) and matched with axial T2w brain
images: green/red = reduction/increase of the metabolite in comparison to healthy controls (see colour bar p values). tNAA and Cho were partially decreased in thalamus
while Glx was partially increased the thalamus, putamen and insular cortex. Further details are presented within the text. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
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In agreement with previous studies including patients with
GTCS we found a reduction of tNAA and Cho in the thalamus,1,5,15
however also signiﬁcant reduction in the cingulum (tNAA, Cho, mI)
and normal mean values in the medial frontal cortex unlike Glx. In
patients suffering from JME, in contrast to GTCS, signiﬁcantly
reduced levels of tNAA in themedial frontal lobewere reported.2,4–
6,32 Thus, our data further support the aspect of different forms of
IGE, which to a certain extent demonstrate different pathophy-
siologies or at least involvement of unequal (sub)-networks.5,13 As
to tNAA a decrease is not necessarily due to reduced cell density.33
The dysfunctional neurometabolism might arise from ‘‘minor’’
regional microdysgenesis on the basis of gene mutations.34
4.2. Metabolic alterations of Glx and Glu
Signiﬁcant increase of Glx has proven valuable in evaluation of
patients with IGE.4,6,15,35 Elevation of Glx, respectively, Glx/Cr was
described as in our study in the thalamus, central region, medial
frontal cortex and cingulum.4,15 The origin of epilepsy is believedto be caused by an inhibitory-excitatory imbalance. Glutamate
(Glu) is the major excitatory neurotransmitter in the brain and
elevation is known to have an excitatory effect.36 Glx (Glu + Gln) is
commonly determined, because the ﬁtting error of the sum is
much smaller than those of the single compounds. Owing to
substantial overlap even at 3 T the sum of Glx is more reliably
determined than the individual components. However, our study
criteria admitted the inclusion of Glu although the single
compound still has to be addressed with caution for reasons
stated above. Thus, a substantial interpretation of different result
with respect to elevation of Glx and normal Glu values, e.g. in the
thalamus is not actually possible. Nevertheless, we found
concomitant elevation of Glx and Glu in the putamen, insular
cortex and interestingly in the fronto-parietal white matter. Glu is
assumed to play an important role in the modulation of thalamic
activity initiated by cortico-thalamic projections.15 Neurons and
glia are tightly coupled with respect to Glu and Gln metabolism,37
though Gln is only synthesised in astrocytes. Disturbance of
excitatory mediator turnover might contribute to seizure genera-
tion. Glial dysfunction could cause low rates of neuron-glia cycling
resulting in a down regulation of the Gln synthetase. Fractional
Table 2
Summary of GTCS patients with abnormal higher or lower metabolic values using a 1.5 standard deviation cut-off from the mean of the control group. Each ﬁeld shows the
included number of patients depending on the inclusion criteria (seemethodical part) and underneath the corresponding percentage. tCr is not shown owing to unremarkable
results [Abbreviations: r-cr-C= right central region Cortex; l-cr-C= left central region Cortex; r-cr-WM=right central regionWhiteMatter; l-cr-WM= left central regionWhite
Matter; r-Ci = right cingulum; l-Ci = left cingulum; r-pCu= right pre-cuneus; l-pCu= left pre-cuneus; r-lf-C = right lateral frontal Cortex; l-lf-C= left lateral frontal Cortex; r-f-
WM=right frontal lobe White Matter; l-f-WM= left frontal lobe White Matter; r-mf-C= right medial frontal Cortex; l-mf-C= left medial frontal Cortex; r-In= right insular; l-
In = left insular; r-Th= right thalamus; l-Th= left thalamus; r-P = right putamen; l-P = left putamen].
Region tNAA low tNAA high Glx low Glx high Glu low Glu high tCho low tCho high mI low mI high
r-cr-C 3/17 (17.6) 0/17 (0) 0/11 (0) 3/11 (27.3) 0/14 (0) 1/14 (7.1) 2/17 (11.8) 0/17 (0) 4/16 (25) 0/16 (0)
l-cr-C 2/18 (11.1) 0/18 (0) 0/11 (0) 3/11 (27.3) 0/16 (0) 2/16 (12.5) 3/18 (16.7) 0/18 (0) 5/18 (27.8) 0/18 (0)
r-cr-WM 2/18 (11.1) 3/18 (16.7) 0/14 (0) 6/14 (42.9) 0/17 (0) 3/17 (17.6) 3/18 (16.7) 1/18 (5.6) 3/18 (16.7) 0/18 (0)
l-cr-WM 2/18 (11.1) 1/18 (5.6) 0/14 (0) 3/14 (21.4) 0/16 (0) 2/16 (12.5) 3/18 (16.7) 1/18 (5.6) 4/18 (22.2) 0/18 (0)
r-Ci 7/18 (38.9) 0/18 (0) 0/17 (0) 3/17 (17.6) 0/17 (0) 0/17 (0) 0/18 (0) 0/18 (0) 3/18 (16.7) 0/18 (0)
l-Ci 3/17 (17.6) 0/17 (0) 0/17 (0) 2/17 (11.8) 1/16 (6.2) 0/16 (0) 1/17 (5.9) 0/17 (0) 3/17 (17.6) 0/17 (0)
r-pCu 0/16 (0) 0/16 (0) 0/14 (0) 0/14 (0) 0/15 (0) 0/15 (0) 0/16 (0) 0/16 (0) 1/16 (6.2) 0/16 (0)
l-pCu 1/16 (6.2) 1/16 (6.2) 1/16 (6.2) 1/16 (6.2) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 1/16 (6.2) 0/16 (0)
r-lf-C 3/18 (16,7) 0/18 (0) 0/17 (0) 1/17 (5.9) 0/17 (0) 1/17 (5.9) 3/18 (16.7) 3/18 (16.7) 2/18 (11.1) 1/18 (5.6)
l-lf-C 1/18 (5.6) 0/18 (0) 0/14 (0) 2/14 (14.3) 0/16 (0) 1/16 (6.2) 0/18 (0) 0/18 (0) 4/18 (22.2) 0/18 (0)
r-ﬂ-WM 1/18 (5.6) 1/18 (5.6) 0/13 (0) 4/13 (30.8) 0/14 (0) 2/14 (14.3) 3/18 (16.7) 1/18 (5.6) 3/18 (16.7) 1/18 (5.6)
l-ﬂ-WM 1/18 (5.6) 1/18 (5.6) 0/13 (0) 3/13 (23.1) 0/15 (0) 1/15 (6.7) 1/18 (5.6) 0/18 (0) 3/18 (16.7) 0/18 (0)
r-mf-C 0/13 (0) 2/13 (15.4) 1/13 (7.7) 3/13 (23.1) 2/13 (15.4) 0/13 (0) 2/13 (15.4) 0/13 (0) 3/13 (23.1) 1/13 (7.7)
l-mf-C 2/12 (16.7) 0/12 (0) 0/13 (0) 7/13 (53.8) 0/13 (0) 1/13 (7.7) 1/13 (7.7) 0/13 (0) 2/13 (15.4) 0/13 (0)
r-In 0/17 (0) 0/17 (0) 0/16 (0) 4/16 (25) 0/16 (0) 1/16 (6.2) 0/17 (0) 1/17 (5.9) 0/17 (0) 0/17 (0)
l-In 1/16 (6.2) 0/16 (0) 0/15 (0) 3/15 (20) 1/16 (6.2) 1/16 (6.2) 0/16 (0) 2/16 (12.5) 0/16 (0) 0/16 (0)
r-Th 2/12 (16.7) 1/12 (8.3) 0/12 (0) 2/12 (16.7) 1/9 (11.1) 3/9 (33.3) 2/12 (16.7) 1/12 (8.3) 1/12 (8.3) 1/12 (8.3)
l-Th 3/13 (23.1) 1/13 (7.7) 0/10 (0) 1/10 (10) 0/9 (0) 0/9 (0) 1/12 (8.3) 0/12 (0) 1/12 (8.3) 0/12 (0)
r-P 0/12 (0) 1/12 (8.3) 0/12 (0) 2/12 (16.7) 0/10 (0) 1/10 (10) 0/12 (0) 1/12 (8.3) 0/12 (0) 1/12 (8.3)
l-P 0/14 (0) 1/14 (7.1) 0/11 (0) 2/11 (18.2) 0/10 (0) 3/10 (30) 0/14 (0) 1/14 (7.1) 0/12 (0) 1/12 (8.3)
M.T. Doelken et al. / Seizure 19 (2010) 485–492 491failure of the Gln synthesis results in an increased glial Glu level,
which could contribute to slower Glu uptake and enhanced Glu
transporter reversal.
4.3. The epileptic network
The brain is sensitive to changeswithin certain networks, with a
consecutive engagement of the rest of the brain due to
interconnected networks.38 In agreement with a recent study
using the tNAA/Cr ratio in a subgroup of patients with JME4 we
found a correlation of tNAA, respectively Glx in the thalamus and
the central region, cingulum and putamen. As to Glx signiﬁcant
correlation was also noticed between the thalamus and the medial
frontal cortex. However, we found no signiﬁcant correlations in the
healthy control group, therefore functional interconnection can be
assumed. Only one other study including 12 JME and 8 GTCS
patients reported a single correlation between thalamic and
insular NAA/Cr.1 However, to our best knowledge, no previous
study reported corresponding tNAA and Glx correlations in the
above mentioned anatomic brain regions. Therefore, in previous
studies it was unclear whether the metabolic alterations reﬂected
involvement of a metabolic network or was uncorrelated.
The basal ganglia are involved in controlling the cortical
excitability,39 also in spread,40,41 modulation42 and persistence of
seizures.43 The feedback from the basal ganglia ismainly inhibitory,
while the motor cortex sends excitatory output. A basal ganglia to
cortex vicious loop with excitatory ﬁring of cortical cells (e.g.
resulting from cortical microdysgenesis) and impaired inhibitory
feedback of the basal ganglia might be the underlying cause of
disease. Excitotoxic lesions, an expected result of hyperexcitability,
wouldbe located in thespeciﬁcnetworks supportingseizures, rather
than distributed to the areas particularly susceptible to diffuse
hypoxia or diffuse excitotoxicity, for example in the hippocampus.
Therefore, it is of special interest, that we found no hippocampal
metabolite alterations in patients with GTCS.
4.4. Clinical data and metabolic alterations
We were not able to demonstrate a metabolic relation to age
and duration of epilepsy, however this might be due to limitedpatient number. As to previous studies1,4,5 our results demonstrate
that poorly controlled seizures are associated with more altered
brain metabolites in the basal ganglia to cortex network. Whether
this is related to the severity or threshold of the underlying
epileptogenic pathology or to the effect of the seizures themselves
remains speculative.1
5. Conclusion
Our results demonstrate certain altered metabolic intercon-
nection of cerebral anatomic regions in patients with GTCS, in
particular themajor role of the basal ganglia-central region relay in
seizure generation. However, the primary locations of seizure
generation and therewith the underlying substrates (e.g. micro-
dysgenesis; cause–effect issue) remain ambiguous. Towhat extend
different clinical IGE syndromesmay depend on speciﬁcmodifying
genes still has to be addressed.44,45
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